1
|
Steinberg RL, Thomas LJ, Mott SL, O'Donnell MA. Bacillus Calmette-Guérin (BCG) Treatment Failures with Non-Muscle Invasive Bladder Cancer: A Data-Driven Definition for BCG Unresponsive Disease. Bladder Cancer 2016; 2:215-224. [PMID: 27376140 PMCID: PMC4927860 DOI: 10.3233/blc-150039] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Objective: To create the first data-driven definition for those unlikely to benefit from further BCG treatment. Materials and Methods: The database created for the Phase 2 BCG-Interferon-α 2B (IFN) study was queried and BCG failure patients were identified (n = 334). Full study protocols have previously been published. Separate models were constructed for analysis of patients with any CIS (pure or concomitant) and pure papillary disease. Variables considered included age, gender, stage, grade, tumor size and focality (for papillary only), number of prior BCG courses, and prior BCG failure interval. Results: Patients with recurrent CIS within 6 months of their most recent prior BCG course (HR 2.56, p < 0.01) and ≥2 prior BCG failures (HR 1.54, p < 0.01) responded worst to repeat intravesical therapy. Those with CIS recurrence at 6–12 months did not differ from those recurring within 6 months (HR = 0.88, p = 0.71). Patients with recurrent papillary disease within 6 months (HR 1.82, p = 0.02), ≥2 BCG failures (HR 1.54, p = 0.03), and multifocal disease (HR 2.05, p < 0.01) responded worst to therapy. Patients with T1 disease remained disease free in 38% of cases (24–51% 95% CI) at 2 years with low rates of progression. Conclusions: Patients who fail two courses of BCG with either persistent or recurrent multifocal papillary disease within 6 months or CIS within 12 months of their prior BCG should be considered BCG unresponsive. Recurrent T1 disease respond reasonably well to another course with low progression rates but further investigation is warranted.
Collapse
Affiliation(s)
| | - Lewis J Thomas
- University of Iowa Department of Urology , Iowa City, IA, USA
| | - Sarah L Mott
- University of Iowa Holden Comprehensive Cancer Center , Iowa City, IA, USA
| | - Michael A O'Donnell
- University of Iowa Department of Urology, Iowa City, IA, USA; University of Iowa Holden Comprehensive Cancer Center, Iowa City, IA, USA
| |
Collapse
|
2
|
Steinberg RL, Thomas LJ, O'Donnell MA. Bacillus Calmette-Guérin (BCG) Treatment Failures in Non-Muscle Invasive Bladder Cancer: What Truly Constitutes Unresponsive Disease. Bladder Cancer 2015; 1:105-116. [PMID: 27376112 PMCID: PMC4927833 DOI: 10.3233/blc-150015] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
Bacillus Calmette-Guérin (BCG) remains the most effective intravesical therapy for non-muscle invasive bladder cancer but will fail in up to 40% of patients. The ability to identify patients who are least likely to respond to further BCG therapy allows urologists to pursue secondary treatments more likely to convey a recurrence or survival benefit to the patient. We examined the literature to determine what constitutes BCG unresponsive disease. After review, we believe that BCG unresponsive disease should be defined as (1) patients with recurrent high grade T1 disease within 6 months of their primary tumor after at least one course of BCG or patients who have failed at least 2 courses of BCG with either (2) persistent or recurrent pure papillary (Ta) disease within 6 months or (3) persistent or recurrent carcinoma in situ (CIS) within 12 months.
Collapse
Affiliation(s)
| | - Lewis J Thomas
- University of Iowa Department of Urology, Iowa City, IA, USA
| | | |
Collapse
|
3
|
Spaliviero M, Dalbagni G, Nielsen M. What to do when bacillus Calmette-Guérin fails. Bladder Cancer 2015. [DOI: 10.1002/9781118674826.ch9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
4
|
Ajili F, Darouiche A, Chebil M, Boubaker S. The efficacy of intravesical bacillus Calmette-Guerin in the treatment of patients with pT1 stage non-muscle-invasive bladder cancer. Ultrastruct Pathol 2013; 37:278-83. [PMID: 23789613 DOI: 10.3109/01913123.2013.792909] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
BACKGROUND pT1 bladder urothelial carcinomas represent a heterogeneous group of tumors with different biologic behaviors, and identifying the subset of tumors that carries a high risk of disease recurrence and progression is therefore important. Induction and maintenance intravesical Bacillus Calmette-Guerin (BCG) has been proven to reduce tumour recurrence and progression. However, no markers are available to predict BCG response. The aim of this study is to evaluate the prognostic factors of stage in predicting recurrence after intravesical adjuvant BCG immunotherapy in patients with NMIBC. METHODS we retrospectively reviewed the clinical and pathologic data of primary NMIBC from 45 patients who were treated with transurethral resection followed by BCG-immunotherapy. Time follow-up was 30 months. The prognostic significance of clinicopathologics characteristics in determining the risk for recurrence after BCG therapy was studied with both univariate and multivariate methods of analysis. RESULTS univariate Cox regression analysis of clinicopathologic characteristics revealed that the rate of recurrence was statistically associated with tumor stage. Indeed, a significant concordance was noted between the EORTC s predicted risks and the actuarial recurrence rate of NMIBC at one year. On the other hand, multivariate analysis using Cox regression based on the AIC criteria and biological considerations, selected the score of recurrence as independent predictor of recurrence. CONCLUSION The conventional clinicopathological factors used in EORTC model are relevant for the assessment of the outcome of pT1 stage bladder tumors treated by BCG immunotherapy. Management of pT1 bladder cancer patients remains one of the most difficult problems in urologic practice. At this time the decision to preserve the bladder or to perform a cystectomy depends on a number of clinicopathologic parameters, but none are able to sufficiently identify patients for the appropriate therapeutic modality. Additional studies using a more large scale of patients will be required to confirm our findings.
Collapse
Affiliation(s)
- Faouzia Ajili
- Laboratory of Human and Experimental Pathology, Pasteur Institue of Tunis, Tunis, Tunisia.
| | | | | | | |
Collapse
|
5
|
Shirakawa H, Kikuchi E, Tanaka N, Matsumoto K, Miyajima A, Nakamura S, Oya M. Prognostic significance of Bacillus Calmette-Guérin failure classification in non-muscle-invasive bladder cancer. BJU Int 2012; 110:E216-21. [DOI: 10.1111/j.1464-410x.2011.10894.x] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
6
|
Affiliation(s)
- Kyung Seok Han
- Department of Urology and Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea
| | - Sung Joon Hong
- Department of Urology and Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea
| |
Collapse
|
7
|
|
8
|
Ignatoff JM, Chen YH, Greenberg RE, Pow-Sang JM, Messing EM, Wilding G. Phase II study of intravesical therapy with AD32 in patients with papillary urothelial carcinoma or carcinoma in situ (CIS) refractory to prior therapy with bacillus Calmette-Guerin (E3897): a trial of the Eastern Cooperative Oncology Group. Urol Oncol 2008; 27:496-501. [PMID: 18639470 DOI: 10.1016/j.urolonc.2008.05.004] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2008] [Revised: 05/11/2008] [Accepted: 05/13/2008] [Indexed: 11/16/2022]
Abstract
OBJECTIVE To assess the safety and effectiveness of AD32, a doxorubicin analogue with little systemic exposure when administered intravesically, in patients with recurrent or refractory superficial urothelial carcinoma (formerly called transitional cell carcinoma [TCC]), or carcinoma in situ (CIS), who have failed prior BCG-based immunotherapy. METHODS Eligible patients received six weekly doses (800 mg) of intravesical AD32 and were evaluated at 12-week intervals for 24 months or until date of worsening disease. Primary analysis was the proportion of all patients recurrence-free at 12 months. Treatment-related and GU-specific toxicities were also examined. All participating institutions submitted the protocol for Institutional Review Board (IRB) approval. RESULTS The study was halted due to unavailability of study drug after accrual of 48 of a planned 64 patients; 42 were included in the analysis. Of these, 28 (67%) were still alive after median follow-up of 61.1 months. Of 21 TCC patients, 18 (85.7%) experienced disease recurrence (median time to recurrence, 5.3 months). Of the 5 CIS patients with complete response (CR), 3 (60%) experienced disease recurrence; (median time to recurrence, 37.3 months). Recurrence-free rates at 12 and 24 months were 20% (90% CI, 7.8%, 36.1%) and 15% (90 CI, 4.9%, 30.2%), respectively, for patients with TCC and 80% (90% CI, 31.4%, 95.8%) at both intervals for CIS patients with CR. Infection was the most common treatment-related toxicity; no grade 4 or higher toxicity was observed. The most common GU-specific toxicity was increased frequency/urgency. CONCLUSIONS AD32 is safe and active for treatment of recurrent or refractory superficial bladder carcinoma. The agent awaits more complete characterization when drug production problems can be solved.
Collapse
Affiliation(s)
- Jeffrey M Ignatoff
- Northwestern University-Feinberg School of Medicine, Chicago, IL 60611, USA.
| | | | | | | | | | | |
Collapse
|
9
|
Fernandez-Gomez J, Solsona E, Unda M, Martinez-Piñeiro L, Gonzalez M, Hernandez R, Madero R, Ojea A, Pertusa C, Rodriguez-Molina J, Camacho JE, Isorna S, Rabadan M, Astobieta A, Montesinos M, Muntañola P, Gimeno A, Blas M, Martinez-Piñeiro JA. Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials. Eur Urol 2007; 53:992-1001. [PMID: 17950987 DOI: 10.1016/j.eururo.2007.10.006] [Citation(s) in RCA: 193] [Impact Index Per Article: 11.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2007] [Accepted: 10/03/2007] [Indexed: 11/16/2022]
Abstract
OBJECTIVES To evaluate the prognostic factors of recurrence and progression after intravesical adjuvant bacillus Calmette-Guérin (BCG) immunotherapy in patients with non-muscle-invasive bladder tumors. METHODS From February 1990 to May 1999, the Spanish Club Urológico Español de Tratamiento Oncológico (CUETO) group has performed four randomized phase 3 studies comparing different intravesical treatments in patients with noninvasive bladder cancer. Data from 1062 evaluable patients treated only with BCG were analyzed. Most patients received BCG once weekly for 6 consecutive weeks and a short-term BCG maintenance (once every 2 wk 6 times more). Associated tumor in situ (TIS) was found in 7.5% (n=80) of cases. There were 22.1% (n=235) patients with T1G3 tumors, 22.9% of whom (n=54) were associated with TIS. Stepwise multivariate Cox regression models with stratification by study and dose were used to assess the independent effect of predictive factors and hazard ratios (HRs) were estimated from the Cox model. RESULTS Multivariate analysis demonstrated that female gender (HR=1.71) compared to male gender, recurrent tumors (HR=1.9) compared to primary tumors, multiplicity, and presence of associated TIS (HR=1.54) increased the risk of recurrence. Recurrent tumors (HR=1.62) compared to primary tumors, high-grade tumors (HR=5.64) compared to G1 tumors, T1 tumors (HR=2.15) compared to Ta tumors, and recurrence at 3-mo cystoscopy (HR=4.6) increased the risk of progression. CONCLUSION Significant independent predictors for recurrence were female gender, history of recurrence, multiplicity, and presence of associated TIS. Age, history of recurrence, high grade, T1 stage, and recurrence at first cystoscopy were independent predictors of progression by multivariate Cox analysis.
Collapse
Affiliation(s)
- Jesus Fernandez-Gomez
- Department of Urology, Hospital Central of Asturias, University of Oviedo, Oviedo, Spain.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Affiliation(s)
- Michael A O'Donnell
- Department of Urology, University of Iowa, 200 Hawkins Dr., 3 RCP, Iowa City, IA 52242-1089, USA.
| | | |
Collapse
|
11
|
Dalbagni G, Russo P, Bochner B, Ben-Porat L, Sheinfeld J, Sogani P, Donat MS, Herr HW, Bajorin D. Phase II trial of intravesical gemcitabine in bacille Calmette-Guérin-refractory transitional cell carcinoma of the bladder. J Clin Oncol 2006; 24:2729-34. [PMID: 16782913 DOI: 10.1200/jco.2005.05.2720] [Citation(s) in RCA: 131] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
Abstract
PURPOSE The aim of this phase II study was to determine the efficacy of gemcitabine administered as an intravesical agent in patients with bacille Calmette-Guérin (BCG) -refractory transitional cell carcinoma of the bladder. PATIENTS AND METHODS Patients with superficial bladder cancer refractory or intolerant to intravesical BCG therapy and refusing a cystectomy were considered eligible for the trial. Eligible patients received two courses of intravesical gemcitabine twice weekly at a dose of 2,000 mg/100 mL for 3 consecutive weeks, with each course separated by 1 week of rest. Patients were evaluated for response at 8 weeks, then every 3 months to 1 year. RESULTS Thirty eligible patients were included on study. The median follow-up for all the patients was 19 months (range, 0 to 35 months). Of the 30 patients, 15 (50%; 95% CI, 32% to 68%) achieved a complete response (CR). Twelve patients had tumor recurrence with a median recurrence-free survival time of 3.6 months (95% CI, 2.9 to 11.0 months). Two patients maintained a CR at 23 and 29 months, respectively. The 1-year recurrence-free survival rate for patients with a CR was 21% (95% CI, 0% to 43%). Two patients progressed to a higher stage while receiving gemcitabine treatment. The median follow-up for patients who did not have a progression or a cystectomy was 19 months (range, 2 to 35 months). Eleven patients (37%) underwent a cystectomy subsequent to gemcitabine therapy. CONCLUSION Gemcitabine has activity in a high-risk patient population and remains a viable option for some patients who refuse cystectomy.
Collapse
Affiliation(s)
- Guido Dalbagni
- Department of Urology, Division of Epidemiology and Biostatistics, the Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Nieder AM, Brausi M, Lamm D, O'Donnell M, Tomita K, Woo H, Jewett MAS. Management of stage T1 tumors of the bladder: International Consensus Panel. Urology 2006; 66:108-25. [PMID: 16399419 DOI: 10.1016/j.urology.2005.08.066] [Citation(s) in RCA: 167] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2005] [Accepted: 08/12/2005] [Indexed: 11/25/2022]
Abstract
The International Consensus Panel on T1 bladder tumors markers reviewed the subject from a clinical perspective. From diagnosis to treatment decisions, what are the important issues in the management of a new patient? The assessment of prognostic factors for progression requires optimal resection and documentation. The role of immediate adjuvant intravesical chemotherapy after resection remains controversial. How often should the upper tract be assessed for tumor recurrence? The decision on whether to attempt bladder conservation with intravesical therapy or to perform a cystectomy is the most difficult issue in the management of superficial bladder cancer today. Finally, what therapies exist if initial intravesical bacille Calmette-Guérin fails to eradicate the disease or prevent recurrence? The panel thoroughly explored all these subjects and has made recommendations with supporting evidence.
Collapse
Affiliation(s)
- Alan M Nieder
- Department of Urology, State University New York, Stony Brook, New York, USA
| | | | | | | | | | | | | |
Collapse
|
13
|
Gurocak S, Sozen S, Erdem O, Ozkan S, Kordan Y, Alkibay T, Akyol G, Bozkirli I. Relation between Cyclooxygenase-2 Expression and Clinicopathologic Parameters with Patient Prognosis in Transitional Cell Carcinoma of the Bladder. Urol Int 2006; 76:51-6. [PMID: 16401921 DOI: 10.1159/000089735] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2005] [Accepted: 07/19/2005] [Indexed: 12/13/2022]
Abstract
OBJECTIVE To evaluate the correlation between cyclooxygenase-2 (Cox-2) expression and clinicopathologic findings with the effect of these variables on prognosis of bladder cancer. METHODS Cox-2 expression was examined immunohistochemically in paraffin blocks of 99 patients. Correlations between Cox-2 expression and variables like cancer stage and grade, number of mitoses, angiolymphatic invasion, number and size of the lesions were determined. RESULTS Cox-2 expression was detected in 52 (52.5%) patients. Univariate regression analysis between Cox-2 expression and clinicopathologic findings showed a significant correlation only in the pathologic stage of the patients (p = 0.048) (OR =2.64, CI = 0.97-7.81). Multivariate regression analysis in stage T1 revealed an increasing number of mitoses as an independent prognostic factor for recurrence (p = 0.002) (OR = 1.5, CI = 1.16-1.92) and progression (p = 0.030) (OR = 8.23, CI = 1.22-55.27) although a prognostic factor was not found for progression in stage T2. CONCLUSION Univariate analysis showed that only the pathologic stage correlated significantly with Cox-2 expression. Cox-2 expression revealed a significant relation with patient prognosis in stage T2 but not in stage T1. These results support the fact that Cox-2 inhibitors may play a role in progression of invasive bladder tumors.
Collapse
Affiliation(s)
- Serhat Gurocak
- Department of Urology, Gazi University School of Medicine, Ankara, Turkey.
| | | | | | | | | | | | | | | |
Collapse
|
14
|
Abstract
PURPOSE We define bacillus Calmette-Guerin (BCG) refractory, high risk, superficial bladder cancer. MATERIALS AND METHODS A total of 93 patients received a 6-week induction course of BCG. They were evaluated for response after 3 and 6 months. Half of the patients received monthly maintenance BCG for 2 years and half did not. In both groups the initial responses to BCG at 3 and 6 months were correlated with subsequent tumor recurrence and progression. RESULTS Of the 93 cases 57% were negative for tumor at 3 months and 43% had residual tumor resected. At 6 months 80% of the patients were tumor-free and 20% had persistent or recurrent tumor. Maintenance BCG did not decrease tumor recurrence further than induction BCG. Subsequent tumor-free interval during 24 months of followup were best predicted by response to BCG after 6 months. CONCLUSIONS A minimum treatment and followup time of 6 months is required to identify high risk, superficial bladder tumors as truly BCG refractory.
Collapse
Affiliation(s)
- Harry W Herr
- Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
| | | |
Collapse
|
15
|
Abstract
Bladder cancer is a common genitourinary malignancy and carcinoma in situ (CIS) of the bladder exists as a potentially aggressive variant of the superficial form of the disease. Treatment must reflect the unpredictable nature of this disease entity. In 1976, the use of intravesical Bacillus Calmette-Guerin (BCG) was described for the management of early stage bladder cancer. A subsequent report demonstrated efficacy in a cohort of patients with CIS of the bladder. Since this time, intravesical BCG has been recognised as the initial therapy for CIS of the bladder. Although a 6-week treatment with intravesical BCG has been established as standard therapy in patients with CIS, there has been no consensus as to the subsequent treatment for patients in the setting of failure to initial management with BCG. In addition, a number of reports have demonstrated an increased potential of adverse effects after repeated treatment with intravesical BCG. A variety of alternative immunological and chemotherapeutic agents have been developed in response to the limitations of BCG for patients with refractory CIS of the bladder. At present, valrubicin remains the only agent that is approved by the US Food and Drug Administration for the specific indication of CIS of the bladder unresponsive to intravesical BCG. Although these agents appear promising, the most efficacious therapy remains to be determined. The specific treatment protocol for refractory CIS of the bladder remains elusive. It is ultimately the combined decision of the clinician and patient to determine which course of management is most beneficial.
Collapse
Affiliation(s)
- J C Kim
- Department of Surgery, University of Chicago, Pritzker School of Medicine, Illinois, USA
| | | |
Collapse
|
16
|
|
17
|
KIM JAMESC, STEINBERG GARYD. THE LIMITS OF BACILLUS CALMETTE-GUERIN FOR CARCINOMA IN SITU OF THE BLADDER. J Urol 2001. [DOI: 10.1016/s0022-5347(05)66518-4] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Affiliation(s)
- JAMES C. KIM
- From the University of Chicago, Pritzker School of Medicine, Chicago, Illinois
| | - GARY D. STEINBERG
- From the University of Chicago, Pritzker School of Medicine, Chicago, Illinois
| |
Collapse
|
18
|
Abstract
The primary role of immunotherapy for bladder cancer is to treat superficial transitional cell carcinomas (ie, carcinoma in situ, Ta, and T1). Immunotherapy in the form of bacille Calmette-Guérin (BCG), interferon, bropirimine, keyhole limpet hemocyanin, and gene therapy is intended to treat existing or residual tumor, to prevent recurrence of tumor, to prevent progression of disease, and to prolong survival of patients. Presently, BCG is commonly used and is the most effective immunotherapeutic agent against superficial transitional cell carcinoma. Data support that BCG has a positive impact on tumor recurrence, disease progression, and survival. Proper attention to maintenance schedules, route of administration, dosing, strains, and viability is essential to obtain the maximum benefits of BCG immunotherapy. This review highlights and summarizes the recent advances concerning immunotherapy, with special emphasis on BCG therapy for transitional cell carcinoma.
Collapse
Affiliation(s)
- A M Kamat
- Department of Urology, PO Box 9251, Health Sciences Center, West Virginia University, Morgantown, WV 26506, USA
| | | |
Collapse
|
19
|
Abstract
Timing of radical cystectomy in patients undergoing treatment and follow up for superficial bladder tumors is discussed with an algorithm for patient decisions.
Collapse
Affiliation(s)
- HW Herr
- Urology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, 10021, New York, NY, USA
| |
Collapse
|
20
|
Olumi AF. A critical analysis of the use of p53 as a marker for management of bladder cancer. Urol Clin North Am 2000; 27:75-82, ix. [PMID: 10696247 DOI: 10.1016/s0094-0143(05)70236-6] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
Delineating the important molecular pathways in carcinogenesis has helped develop and advance the field of molecular diagnosis. Bladder cancer has served as an excellent model in translating some of the advances from the laboratory to clinical settings. Many investigators have examined the use of p53 to help manage patients with bladder cancer who are at high risk of tumor progression. This article reviews the clinical studies that have used p53 as a marker in bladder carcinoma and concludes by determining whether routine assessment of the p53 tumor suppressor gene/protein is indicated at this time.
Collapse
Affiliation(s)
- A F Olumi
- Division of Urologic Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
| |
Collapse
|
21
|
Affiliation(s)
- A M Kamat
- Department of Urology, West Virginia University School of Medicine, Morgantown, USA
| | | |
Collapse
|
22
|
Bui TT, Schellhammer PF. Additional bacillus Calmette-Guérin therapy for recurrent transitional cell carcinoma after an initial complete response. Urology 1997; 49:687-90; discussion 690-1. [PMID: 9145971 DOI: 10.1016/s0090-4295(97)00067-8] [Citation(s) in RCA: 50] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
OBJECTIVES To determine the success of additional bacillus Calmette-Guérin (BCG) therapy for transitional cell carcinoma recurring after a complete response (CR) to the initial treatment course of BCG. METHODS All patients treated with BCG with a minimum follow-up of 5 years were reviewed to identify complete responders who subsequently recurred and received additional BCG therapy. The duration of initial response and the incidence and duration of a second CR were recorded. RESULTS Of 11 patients with an initial CR to a 6-week course of BCG, 9 (82%) achieved a second CR and 5 of the 9 (42%) maintained tumor-free status beyond 5 years of follow-up (median 87 months, range 64 to 110). Patients who again recurred after the second CR did not benefit from further BCG therapy. CONCLUSIONS A repeat course of BCG is a reasonable option of therapy for transitional cell carcinoma that has recurred after a CR to a prior course of BCG. Careful monitoring by cytology, cystoscopy, and biopsy is mandatory to direct nonresponders to prompt alternative therapy and to ensure continued disease-free status among responders.
Collapse
Affiliation(s)
- T T Bui
- Department of Urology, Virginia Prostate Center, Sentara Cancer Institute, Norfolk, Virginia, USA
| | | |
Collapse
|
23
|
Sokoloff MH, Belldegrun A. Immunotherapy and Gene Therapy for Genitourinary Malignancies. Int J Urol 1996. [DOI: 10.1111/j.1442-2042.1996.tb00336.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
24
|
Kanamaru H, Saikawa S, Muranaka K, Mori H, Akino H, Miwa Y, Nakamura N, Fujita T, Okada K. Early disease progression after intravesical bacillus Calmette-Guérin (BCG) therapy for superficial bladder cancer. Int J Urol 1996; 3:18-22. [PMID: 8646593 DOI: 10.1111/j.1442-2042.1996.tb00623.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
BACKGROUND Disease progression after Bacillus Calmette-Guérin (BCG) instillation therapy for bladder cancer is not rare. The purpose of this study was to evaluate the outcome of patients treated with BCG for superficial bladder cancer, focusing on the patients who developed invasive disease during follow-up. The possible mechanism and risk factors for early progression after BCG therapy are discussed. METHODS A total of 25 patients with superficial bladder cancer (pTa, pT1 and/or pTis) were treated with intravesical BCG instillation (80 mg in 80 ml saline) once a week for eight weeks. Four of the 25 patients received maintenance therapy with BCG (once a month for 3 to 10 months). Patients were followed every three months and underwent cystoscopy, biopsy, and urinary cytology at these intervals. Disease progression was defined as invasion to muscle or prostate, or development of metastatic disease. Clinicopathological features of the patients, especially those with progression, were analyzed. RESULTS Progression was observed in six of the 25 patients, (including four of 19 patients with carcinoma in situ and two of five patients treated prophylactically with BCG). The average time to progression was 8.7 months. Four patients died of cancer despite intensive treatment. Two patients are alive: one without evidence of disease after cystectomy and the other with metastatic disease. CONCLUSIONS Proper patient selection, careful follow-up, and immediate aggressive therapy in case of progression were considered to be important factors to obtain satisfactory results with BCG therapy for bladder cancer.
Collapse
Affiliation(s)
- H Kanamaru
- Department of Urology, Fukui Medical School, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Kurth KH, Schellhammer PF, Okajima E, Akdas A, Jakse G, Herr HW, Calais da Silva F, Fukushima S, Nagayama T. Current methods of assessing and treating carcinoma in situ of the bladder with or without involvement of the prostatic urethra. Int J Urol 1995; 2 Suppl 2:8-22. [PMID: 7553309 DOI: 10.1111/j.1442-2042.1995.tb00475.x] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Affiliation(s)
- K H Kurth
- AMC Department of Urology, Amsterdam, The Netherlands
| | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Affiliation(s)
- M A Hudson
- Division of Urological Surgery, Washington University School of Medicine, St. Louis, Missouri
| | | |
Collapse
|
27
|
c KHK, cc PFS, cc EO, Akdas A, Jakse G, Hen HW, Silva FCD, Fukushima S, Nagayama T. CURRENT METHODS OF ASSESSING AND TREATING CARCINOMA IN SITUOF THE BLADDER WITH OR WITHOUT INVOLVEMENT OF THE PROSTATIC URETHRA. Int J Urol 1995. [DOI: 10.1111/j.1442-2042.1995.tb00068.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|